Literature DB >> 15113580

Stereospecific chemical and enzymatic stability of phosphoramidate triester prodrugs of d4T in vitro.

Dario Siccardi1, Mark Gumbleton, Yadollah Omidi, Chistopher McGuigan.   

Abstract

The phosphoramidate triester prodrug approach is widely used to deliver nucleotide forms of nucleoside analogues into target cells. We investigated the stereoselective stability of a series of prodrugs of the anti-HIV agent 2',3'-didehydro-2',3'-dideoxythymidine (d4T). Chemical stability was evaluated in phosphate buffer at pH values of biological relevance (i.e. pH 2.0, 4.6, 7.4). Enzymatic stability was tested in human plasma, in Caco-2 cell homogenates and monolayers and in rat liver. The compounds were relatively stable to chemical hydrolysis. Between 50 and 70% of unchanged prodrug was recovered after 16h incubation in human plasma, with no stereoselective preference for phosphate diastereoisomers. The p-OMe phenyl derivative, however, was an exception and only 5% of one diastereoisomer was recovered. In Caco-2 cells the stability and stereoselectivity largely depended on the experimental conditions: high enzymatic activity and stereoselectivity was observed in cell homogenates, but not in monolayers. In rat liver S9 fractions the stability profile was similar to that in Caco-2 cells and carboxyl ester cleavage appeared to be the sole mechanism of degradation in both media. The large and unpredictable differences in stereoselective metabolic rate of the pronucleotide series here presented suggest that in vivo circulating levels of intact prodrug could exert profoundly different activity or toxicity due to preferential body distribution of one diastereoisomeric form.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113580     DOI: 10.1016/j.ejps.2004.02.006

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  3 in total

Review 1.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues.

Authors:  Larryn W Peterson; Charles E McKenna
Journal:  Expert Opin Drug Deliv       Date:  2009-04       Impact factor: 6.648

2.  Aryl phosphoramidates of 5-phospho erythronohydroxamic acid, a new class of potent trypanocidal compounds.

Authors:  Gian Filippo Ruda; Pui Ee Wong; Vincent P Alibu; Suzanne Norval; Kevin D Read; Michael P Barrett; Ian H Gilbert
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

Review 3.  Blood-brain barrier transport machineries and targeted therapy of brain diseases.

Authors:  Jaleh Barar; Mohammad A Rafi; Mohammad M Pourseif; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-12-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.